title: Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer.
abstract: BACKGROUND
  Low survival outcomes have been reported for the treatment of locally advanced non small cell lung cancer (LA-NSCLC) with the standard of care treatment of concurrent chemoradiation (cCRT). We present our experience of dose escalation using stereotactic body radiosurgery (SBRT) following conventional cCRT for patients with LA-NSCLC.
  
  
  METHODS
  Sixteen patients with a median age of 67.5 treated with fractionated SBRT from 2010 to 2012 were retrospectively analyzed. Nine (56%) of the patients had stage IIIB, 6 (38%) has stage IIIA, and 1 (6%) had recurrent disease. Majority of the patients (63%) presented with N2 disease. All patients had a PET CT for treatment planning. Patients received conventional cCRT to a median dose of 50.40 Gy (range 45-60) followed by an SBRT boost with an average dose of 25 Gy (range 20-30) given over 5 fractions.
  
  
  RESULTS
  With a median follow-up of 14 months (range, 1-14 months), 1-year overall survival (OS), progression free survival (PFS), local control (LC), regional control (RC), and distant control (DC) rates were, 78%, 42%, 76%, 79%, and 71%, respectively. Median times to disease progression and regional failure were 10 months and 18 months, respectively. On univariate analysis, advanced age and nodal status were worse prognostic factors of PFS (p < 0.05). Four patients developed radiation pneumonitis and one developed hemoptysis. Treatment was interrupted in one patient who required hospitalization due to arrhythmias and pneumonia.
  
  
  CONCLUSIONS
  Risk adaptive dose escalation with SBRT following external beam radiotherapy is possible and generally tolerated treatment option for patients with LA-NSCLC.
authors.forename: Sana D
authors.initials: SD
authors.lastname: Karam
authors.forename: Zachary D
authors.initials: ZD
authors.lastname: Horne
authors.forename: Robert L
authors.initials: RL
authors.lastname: Hong
authors.forename: Don
authors.initials: D
authors.lastname: McRae
authors.forename: David
authors.initials: D
authors.lastname: Duhamel
authors.forename: Nadim M
authors.initials: NM
authors.lastname: Nasr
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000601:surgery*; D059248:Chemoradiotherapy / Q000379:methods; D018572:Disease-Free Survival; D005260:Female; D057918:Fiducial Markers; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011874:Radiometry; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods